TARS — Tarsus Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $3.45bn
- $3.12bn
- $182.95m
- 61
- 17
- 81
- 53
Annual income statement for Tarsus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 57 | 25.8 | 17.4 | 183 |
| Cost of Revenue | |||||
| Gross Profit | — | 55 | 24.9 | 15.9 | 170 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 27 | 69.2 | 88.5 | 161 | 305 |
| Operating Profit | -27 | -12.2 | -62.7 | -143 | -123 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -26.8 | -13.8 | -62.1 | -136 | -116 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -26.8 | -13.8 | -62.1 | -136 | -116 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -26.8 | -13.8 | -62.1 | -136 | -116 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -26.8 | -13.8 | -62.1 | -136 | -116 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.31 | -0.673 | -2.52 | -4.62 | -3.02 |